Literature DB >> 27787263

Serum alanine aminotransferase levels and all-cause mortality.

Erica Karaphillis1, Ryan Goldstein, Sharif Murphy, Rehan Qayyum.   

Abstract

BACKGROUND AND OBJECTIVES: Studies have examined the relationship between serum alanine aminotransferase (ALT) and mortality with inconsistent results. Our aims were to examine the association of normal range serum ALT with mortality, to explore a nonlinear relationship between ALT and mortality, and to investigate whether age modifies this relationship. STUDY: We used the continuous National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010. Vital status of the participants was obtained by probabilistic matching between NHANES and the National Death Index. Cox proportional models were used to examine the relationship with and without adjustment for age, sex, race, BMI, hypertension, diabetes, alcohol use, serum triglycerides, prescription drug use, and glomerular filtration rate, and accounting for the sampling methodology of NHANES. Nonlinear relationship was examined using spline (single knot at 17 U/l) regression. Interaction terms were used to examine effect modification by age.
RESULTS: Higher serum ALT was associated with lower all-cause mortality [adjusted hazard ratio (HR)/ALT increment=0.98, 95% confidence interval (CI)=0.97-0.99]; however, this relationship was nonlinear and present only until 17 U/l (adjusted HR/ALT increment=0.93, 95% CI=0.91-0.95) and not thereafter. Age modified the relationship between ALT and mortality; elderly patients (>64 years) had a 6% lower adjusted mortality risk than younger (<35 years) participants (HR/ALT increment=0.94, 95% CI=0.91-0.96; interaction P<0.001).
CONCLUSION: Increase in serum ALT within the normal range is initially associated with lower mortality, but has no effect after 17 U/l. The elderly show a significantly larger decrease in mortality with an increase in ALT than younger individuals. The mechanisms underlying this relationship need further exploration.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27787263     DOI: 10.1097/MEG.0000000000000778

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Association between alanine aminotransferase and all-cause mortality rate: Findings from a study on Japanese community-dwelling individuals.

Authors:  Ryuichi Kawamoto; Asuka Kikuchi; Taichi Akase; Daisuke Ninomiya; Yoshio Tokumoto; Teru Kumagi
Journal:  J Clin Lab Anal       Date:  2022-04-18       Impact factor: 3.124

2.  High Aspartate Aminotransferase/Alanine Aminotransferase Ratio May Be Associated with All-Cause Mortality in the Elderly: A Retrospective Cohort Study Using Artificial Intelligence and Conventional Analysis.

Authors:  Kei Nakajima; Mariko Yuno; Kazumi Tanaka; Teiji Nakamura
Journal:  Healthcare (Basel)       Date:  2022-04-02

3.  Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study.

Authors:  Jin Hwa Park; Jun Choi; Dae Won Jun; Sung Won Han; Yee Hui Yeo; Mindie H Nguyen
Journal:  J Clin Med       Date:  2019-09-11       Impact factor: 4.241

Review 4.  Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs.

Authors:  Eleftheria Galatou; Elena Mourelatou; Sophia Hatziantoniou; Ioannis S Vizirianakis
Journal:  Antioxidants (Basel)       Date:  2022-05-27

5.  The association between serum liver enzymes and cancer mortality.

Authors:  Somaya Albhaisi; Rehan Qayyum
Journal:  Clin Exp Med       Date:  2021-07-08       Impact factor: 3.984

6.  Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.

Authors:  James H Lewis; Michel Jadoul; Geoffrey A Block; Melanie P Chin; Deborah A Ferguson; Angie Goldsberry; Colin J Meyer; Megan O'Grady; Pablo E Pergola; Scott A Reisman; W Christian Wigley; Glenn M Chertow
Journal:  Clin Transl Sci       Date:  2020-09-03       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.